MHRA expands public route for reporting suspicious online medicine sellers
The Medicines and Healthcare products Regulatory Agency is directing the public to a dedicated reporting service for websites and online sellers that may be offering medicines or medical devices illegally in the UK. The message is straightforward: suspicious sales online should not be ignored, and the agency accepts reports from anyone, including anonymous submissions.
The service is aimed at a familiar but persistent public health problem. Illegal online medicine sales can place patients at risk because products marketed outside regulated channels may be counterfeit, substandard, improperly stored, or sold without the safeguards that normally govern UK supply. In practice, that means the patient may not know what is in the product, whether it was manufactured properly, or whether it is suitable for the condition it is being used to treat.
What the reporting pathway asks people to provide
The reporting process asks for the reason a seller is being reported and for identifying details such as a social media name or website address. The agency also invites supporting material when available, including photographs of the product and packaging, screenshots of the website or online listing, the seller’s name or telephone number, and emails, sales receipts, or messages. Those details can help regulators assess whether a seller is operating outside the law and whether further action is needed.
The design of the service matters because online sales often leave a thin trail. A website can disappear, a social media account can be renamed, and a seller can shift to a new platform quickly. Packaging images, communications, and transaction records provide practical evidence that may help connect one listing to another and identify patterns of illegal distribution. In a setting where speed and traceability often determine whether a product can be investigated, those details are not administrative extras. They are often the only usable evidence.
Anyone can submit a report, and anonymity is permitted. That lowers the barrier for patients, carers, pharmacists, and other members of the public who may hesitate to come forward if they believe a seller is operating unlawfully but do not want their identity attached to the complaint.
A separate route for side effects and product safety concerns
The MHRA also makes a clear distinction between reporting an illegal seller and reporting an adverse reaction. If the problem involves side effects from a medicine or a medical device, the agency directs users to the Yellow Card reporting service instead. In clinical terms, that separation is important. A complaint about an illicit seller is a regulatory and enforcement issue, while a side effect report contributes to pharmacovigilance and device safety monitoring.
A patient who buys a product from a suspicious website and then develops symptoms may actually need both pathways. One report can help authorities assess the seller’s legitimacy, while the other can feed into safety surveillance if the product itself or its use appears to have caused harm. The two systems serve different purposes, but they sit on the same safety continuum.
Why illegal online supply remains a patient safety issue
The rise of online medicine purchasing has created a direct channel between sellers and consumers, often bypassing the checks that are routine in legitimate pharmacy supply. That can create real clinical danger. Some products may be sold without proper authorization, some may be mislabeled, and some may be packaged to look authentic while containing the wrong ingredient or dose. For medical devices, the same concern applies to items that may not meet the standards expected in regulated UK distribution.
The risk extends beyond the product itself. Patients buying from illegitimate sellers may not receive the counseling that accompanies lawful supply, including dosage instructions, warnings about interactions, contraindications, storage conditions, or what to do if the treatment does not work. In the wrong hands, a shortcut purchase can become a delayed diagnosis, a treatment failure, or an avoidable adverse event.
The reporting service is a regulatory tool, but it also functions as a public health early-warning system. Patterns in complaints can reveal recurring sellers, repeated product names, and the kinds of fraudulent claims that draw patients in. That information can support action against websites or accounts that continue to market medicines or devices outside legal controls.
Direct contact is available when the online service is not enough
For people who have difficulty using the service, MHRA provides direct contact details for help, including an email address and a telephone line with weekday opening hours. That support channel may matter for patients or professionals who need assistance submitting a report or clarifying which route to use.
The agency’s instruction is narrow but clinically relevant: if a website or online seller appears to be offering medicines or medical devices illegally, report it. If the concern is a side effect, use the Yellow Card system instead. One pathway is for enforcement and market surveillance; the other is for safety monitoring. Keeping those routes separate helps regulators act on the right kind of risk.
For patients, the practical consequence is immediate. Suspicious sellers can be reported anonymously, evidence can be attached when available, and the information may help the MHRA identify unlawful supply before more people are exposed to unsafe products.